Twist Bioscience
455 Mission Bay Blvd South
San Francisco
California
94158
United States
296 articles about Twist Bioscience
-
Twist Bioscience Launches High Throughput Antibody Production Platform
4/28/2022
Twist Bioscience Corporation announced the launch of the Twist High Throughput Antibody Production, a gene-to-antibody production platform that enables customers to turn candidate DNA sequences into purified antibodies for therapeutic discovery and screening applications.
-
Twist Bioscience Announces Promotions and Changes to Executive Leadership Team
4/21/2022
Twist Bioscience Corporation today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development.
-
Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies
4/7/2022
Twist Bioscience Corporation and MediSix Therapeutics today announced a collaboration to discover novel antibodies against five undisclosed targets.
-
Twist Bioscience and Ginkgo Bioworks Sign New Collaboration
4/5/2022
Twist Bioscience Corporation and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a new supply agreement expanding the depth and breadth of the collaboration between two of the leading organizations in the synthetic biology ecosystem.
-
Twist Bioscience Launches Synthetic RNA Positive Controls for SARS-CoV-2 Encapsulated in Imagene’s Stainless Steel Capsules
3/21/2022
Twist Bioscience Corporation today announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated in proprietary stainless steel minicapsules provided by Imagene SA.
-
Abveris Named as One of the Best Places to Work
3/10/2022
The Business Intelligence Group today announced that it has awarded Abveris a division of Twist Bioscience, a Best Places to Work 2022.
-
Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
3/9/2022
Twist Bioscience Corporation and Kriya Therapeutics, Inc. today announced an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications.
-
Kriya forged an antibody discovery agreement with Twist to support the delivery of antibodies with AAV gene therapy in therapeutic oncology applications.
-
Twist Bioscience to Present at Upcoming Virtual Conferences - Feb 28, 2022
2/28/2022
Twist Bioscience Corporation announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the following upcoming virtual investor conferences:.
-
Twist Bioscience Becomes Digital Preservation Coalition Supporter
2/28/2022
Twist Bioscience Corporation today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where members and solution providers can collaborate.
-
Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/15/2022
Twist Bioscience Corporation today announced the closing of its upsized underwritten public offering of 5,227,272 shares of its common stock at a public offering price of $55.00 per share.
-
Twist Bioscience Announces Pricing of an Upsized $250 Million Public Offering of Common Stock
2/11/2022
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the pricing of an upsized, underwritten public offering of 4,545,454 shares of its common stock at a price to the public of $55.00 per share.
-
Twist Bioscience to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
2/10/2022
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference.
-
Twist Bioscience Announces Proposed Public Offering of Common Stock - Feb 09, 2022
2/9/2022
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced that it intends to offer and sell in an underwritten public offering up to $200 million of shares of its common stock.
-
Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools
2/7/2022
Twist Bioscience Corporation and Eleven Therapeutics today announced that they have created a replicon tool that could be used for studying viral genome replication and antiviral drug screening as well as vaccine and therapeutic development.
-
Twist Bioscience Reports First Quarter 2022 Financial Results
2/4/2022
Twist Bioscience Corporation today reported financial results and business highlights for the first quarter of fiscal 2022 ended December 31, 2021.
-
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
2/1/2022
Twist Bioscience Corporation and Abcam announced a licensing agreement under which Abcam will use a proprietary Twist VHH phage library for antibody discovery, development and commercialization for diagnostic and research applications.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
-
Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
1/25/2022
Twist Bioscience Corporation and Artisan Development Labs Inc. today announced a collaboration to discover novel antibodies against five undisclosed targets.
-
Biotech companies are partnering with other biotech companies to combine their cutting-edge technology platforms in hopes of opening up new avenues for drug development.